NVO
NYSEHealthcareLoading…
Novo Nordisk A/S Common Stock
Sector: Healthcare•United States•Market Cap: $161.5B
Related News
Latest stories connected to NVO
10/39More news →
- RS 66Novo Nordisk's Awiqli Gets FDA Approval for Type II DiabetesZacks Investment Research•6h ago•Original source
- RS 66Articles of Association for Novo Nordisk A/S 2026GlobeNewsWire•12h ago•Original source
- RS 66US FDA approves Novo's insulin injection for type 2 diabetesReuters•23h ago•Original source
- RS 66Novo Nordisk (NVO) Stock Slides as Market Rises: Facts to Know Before You TradeZacks Investment Research•2d ago•Original source
- RS 66NVO Eyes Global Expansion of Diabetes Drug After Strong Phase II DataZacks Investment Research•2d ago•Original source
- RS 66Down Near Its 5-Year Low, Is Novo Nordisk Stock Too Cheap to Pass Up?The Motley Fool•Mar 20, 2026•Original source
- RS 66China expresses hopes over Novo Nordisk's presence in marketReuters•Mar 20, 2026•Original source
Financials
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|
| Revenue | 297.20B | 290.40B | 232.26B | 176.95B | 140.80B | 126.95B | 122.02B | 111.83B | 111.70B | 111.78B |
| Cost of Revenue | 58.43B | 44.52B | 35.77B | 28.45B | 23.66B | 20.93B | 20.09B | 17.62B | 17.63B | 17.18B |
| Gross Profit | 238.77B | 245.88B | 196.50B | 148.51B | 117.14B | 106.01B | 101.93B | 94.21B | 94.06B | 94.60B |
| Research and Development Expenses | 50.04B | 48.06B | 32.44B | 24.05B | 17.77B | 15.46B | 14.22B | 14.80B | 14.01B | 14.56B |
| General and Administrative Expenses | 5.16B | 5.28B | 4.86B | 4.47B | 4.05B | 3.96B | 4.01B | 3.92B | 3.78B | 3.96B |
| Selling and Marketing Expenses | 62.71B | 62.10B | 56.74B | 46.22B | 37.01B | 32.93B | 31.82B | 29.40B | 28.34B | 28.38B |
| Selling General and Administrative Expenses | 67.87B | 67.38B | 61.60B | 50.68B | 41.06B | 36.89B | 35.83B | 33.31B | 32.12B | 32.34B |
| Other Expenses | -8.98B | 2.10B | -119.00M | -1.03B | -332.00M | -460.00M | -600.00M | -1.15B | -1.04B | -737.00M |
| Operating Expenses | 108.94B | 117.54B | 93.92B | 73.70B | 58.50B | 51.89B | 49.45B | 46.97B | 45.10B | 46.16B |
| Cost and Expenses | 167.36B | 162.06B | 129.69B | 102.14B | 82.16B | 72.82B | 69.54B | 64.58B | 62.73B | 63.35B |
| Net Interest Income | 2.77B | 198.00M | 527.00M | -139.00M | -58.00M | -188.28M | -430.32M | -106.00M | -89.00M | -98.00M |
| Interest Income | 9.29B | 1.84B | 1.07B | 239.00M | 231.00M | 312.56M | 64.15M | 51.00M | 69.00M | 52.00M |
| Interest Expense | 6.52B | 1.64B | 542.00M | 378.00M | 289.00M | 500.84M | 494.47M | 85.00M | 90.00M | 65.00M |
| Depreciation and Amortization | 14.67B | 8.54B | 9.41B | 7.36B | 6.03B | 5.75B | 5.66B | 3.92B | 3.18B | 3.19B |
| EBITDA | 143.94B | 137.38B | 114.63B | 76.80B | 65.39B | 59.27B | 54.43B | 51.63B | 51.95B | 51.06B |
| EBIT | 129.83B | 128.83B | 105.22B | 69.44B | 59.37B | 53.52B | 48.77B | 47.70B | 48.77B | 47.86B |
| Non Operating Income Excluding Interest | 0 | -492.00M | -2.64B | 5.37B | -725.00M | 606.00M | 3.71B | -452.00M | 197.00M | 569.00M |
| Operating Income | 129.83B | 128.34B | 102.57B | 74.81B | 58.64B | 54.13B | 52.48B | 47.25B | 48.97B | 48.43B |
| Total Other Income Expenses Net | -4.31B | -1.15B | 2.10B | -5.75B | 436.00M | -996.00M | -3.93B | 367.00M | -287.00M | -634.00M |
| Income Before Tax | 125.53B | 127.19B | 104.67B | 69.06B | 59.08B | 53.13B | 48.55B | 47.62B | 48.68B | 47.80B |
| Income Tax Expense | 27.03B | 26.20B | 20.99B | 13.54B | 11.32B | 10.99B | 9.60B | 8.99B | 10.55B | 9.87B |
| Net Income From Continuing Operations | 98.50B | 100.99B | 83.68B | 55.52B | 47.76B | 42.14B | 38.95B | 38.63B | 38.13B | 37.92B |
| Net Income From Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Adjustments To Net Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | 102.43B | 100.99B | 83.68B | 55.52B | 47.76B | 42.14B | 38.95B | 38.63B | 38.13B | 37.92B |
| Net Income Deductions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Borrom Line Net Income | — | — | — | — | — | — | — | — | — | — |
| EPS | 23.06 | 22.67 | 18.67 | 12.26 | 10.4 | 9.03 | 8.21 | 7.98 | 7.71 | 7.5 |
| EPS Diluted | 23.03 | 22.63 | 18.62 | 12.22 | 10.37 | 9.01 | 8.19 | 7.97 | 7.7 | 7.48 |
| Weighted Average SHS Out | 4.45B | 4.45B | 4.48B | 4.53B | 4.59B | 4.67B | 4.75B | 4.84B | 4.96B | 5.07B |
| Weighted Average SHS Out Dil | 4.45B | 4.46B | 4.49B | 4.54B | 4.61B | 4.68B | 4.76B | 4.85B | 4.96B | 5.07B |
| Fiscal Year (FMP) | 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | 2.02K |
| Gross Profit Margin | 0.8 | 0.85 | 0.85 | 0.84 | 0.83 | 0.84 | 0.84 | 0.84 | 0.84 | 0.85 |
| R&D to Revenue | 0.17 | 0.17 | 0.14 | 0.14 | 0.13 | 0.12 | 0.12 | 0.13 | 0.13 | 0.13 |
| SG&A to Revenue | 0.02 | 0.02 | 0.02 | 0.03 | 0.03 | 0.03 | 0.03 | 0.04 | 0.03 | 0.04 |
| Interest Burden | 0.97 | 0.99 | 0.99 | 0.99 | 1 | 0.99 | 1 | 1 | 1 | 1 |
| EBIT Margin | 0.44 | 0.44 | 0.45 | 0.39 | 0.42 | 0.42 | 0.4 | 0.43 | 0.44 | 0.43 |
| EBITDA Margin | 0.48 | 0.47 | 0.49 | 0.43 | 0.46 | 0.47 | 0.45 | 0.46 | 0.47 | 0.46 |
| EBT per EBIT | 0.97 | 0.99 | 1.02 | 0.92 | 1.01 | 0.98 | 0.93 | 1.01 | 0.99 | 0.99 |
| Effective Tax Rate | 0.22 | 0.21 | 0.2 | 0.2 | 0.19 | 0.21 | 0.2 | 0.19 | 0.22 | 0.21 |
| Tax Burden | 0.78 | 0.79 | 0.8 | 0.8 | 0.81 | 0.79 | 0.8 | 0.81 | 0.78 | 0.79 |
| Cont. Operations Profit Margin | 0.33 | 0.35 | 0.36 | 0.31 | 0.34 | 0.33 | 0.32 | 0.35 | 0.34 | 0.34 |
| Bottom Line Profit Margin | 0.33 | 0.35 | 0.36 | 0.31 | 0.34 | 0.33 | 0.32 | 0.35 | 0.34 | 0.34 |
| Operating Cycle | 402.98 | 444.76 | 442.92 | 431.52 | 424.03 | 66.38 | 59.71 | 426.22 | 395.2 | 383.64 |
| Fwd PEG Ratio | 8.49 | 1.28 | 0.71 | 2.14 | 2.32 | 2.37 | 8.16 | 5.37 | 7.61 | 1.61 |
| Earnings Yield | 0.07 | 0.04 | 0.03 | 0.03 | 0.03 | 0.04 | 0.04 | 0.05 | 0.05 | 0.06 |
| Income Quality | 1.16 | 1.2 | 1.3 | 1.42 | 1.15 | 1.23 | 1.2 | 1.16 | 1.08 | 1.27 |